setrusumab

Ultragenyx Pharmaceutical's stock plunged 42% after failing to disclose setrusumab Phase 3 trial failure, triggering securities litigation with April 6, 2026 lead plaintiff deadline.

Class action filed against Ultragenyx ($RARE) alleging misrepresented setrusumab trial data. Investors purchasing August 2023-December 2025 may recover damages.

Class action suits filed against Ultragenyx and Mereo BioPharma following failed Phase III trials for setrusumab, with stock prices crashing 42.32% and 87.7% respectively.

Class action lawsuit filed against $UGXY alleging securities fraud over misleading setrusumab trial data and OI patient safety disclosures.

Investors in $MREO have until April 6, 2026 to join securities class action alleging misleading statements about failed Phase 3 setrusumab trials.

Ultragenyx Pharmaceutical faces securities fraud lawsuit after setrusumab trials failed. Stock crashed 42% in December; investors have until April 6, 2026, to join action.

Ultragenyx faces a securities class action alleging misrepresentations about its setrusumab drug's efficacy for osteogenesis imperfecta. Affected investors have until April 6, 2026 to serve as lead plaintiff.

Ultragenyx Pharmaceutical faces securities lawsuit after setrusumab trial failure caused 42% stock decline. Lead plaintiff deadline April 6, 2026.

Securities class action filed against $MREO for allegedly misleading investors about Phase 3 clinical trial results. Lead plaintiff deadline April 6, 2026.

Robbins LLP sues Mereo BioPharma over setrusumab trial failures; stock crashes 87.7% to $0.29 after December 29 announcement.

Class action lawsuit filed against $UGDX alleging false statements about setrusumab efficacy for Osteogenesis Imperfecta, claiming Phase III results overstated drug benefits.

Law firm Kahn Swick & Foti files class action against $UGXX over failed Phase 3 trial for rare bone disease drug setrusumab. Investors can apply as lead plaintiffs by April 6.

Mereo BioPharma faces securities class action for allegedly concealing failed Phase 3 trials for setrusumab. Investors have until April 6, 2026 to act.

Class action lawsuit filed against $UGXY alleging securities fraud related to setrusumab clinical trial data. Investors from August 2023 to December 2025 eligible.

Ultragenyx faces securities lawsuit over delayed disclosure of failed Phase 3 trial. Investors must file lead plaintiff claims by April 6, 2026.

Mereo BioPharma faces securities litigation alleging it misled investors about Phase 3 clinical trial results for setrusumab, failing to disclose the trials missed primary endpoints.

Portnoy Law Firm filed securities class action against Ultragenyx Pharmaceutical, alleging the company made false statements about investigational drug setrusumab and concealed material clinical trial risks.

Ultragenyx faces securities lawsuit after failing to disclose setrusumab trial failure, causing 42% stock drop. Investors claim company withheld material information before December announcement.

Ultragenyx faces securities lawsuit alleging false claims about drug setrusumab for bone disease. Investors have until April 6, 2026 deadline to join class action.

Ultragenyx faces class action lawsuit for allegedly misleading investors about setrusumab efficacy and failing to disclose Phase III trial risks adequately.